achn-490 and Extensively-Drug-Resistant-Tuberculosis

achn-490 has been researched along with Extensively-Drug-Resistant-Tuberculosis* in 1 studies

Other Studies

1 other study(ies) available for achn-490 and Extensively-Drug-Resistant-Tuberculosis

Article	Year
FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs. Clinical pharmacology and therapeutics, 2021, Volume: 109, Issue:4 Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Antifungal Agents; Cross Infection; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Liposomes; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Nitroimidazoles; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Sisomicin; United States; United States Food and Drug Administration	2021

Article

Year

FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs.

Clinical pharmacology and therapeutics, 2021, Volume: 109, Issue:4

Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Antifungal Agents; Cross Infection; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Liposomes; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Nitroimidazoles; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Sisomicin; United States; United States Food and Drug Administration

2021